DEK and melanoma: To demonstrate that the downregulation of DEK downstream of CELF1 depletion was the cause, not the consequence of cell cycle arrest, representative melanoma cells (UACC-62) were treated with well-known pharmacological inhibitors of BRAF (vemurafenib), MEK (U0126), or PI3K (GDC-0941).